rss
J Clin Pathol 66:256-259 doi:10.1136/jclinpath-2012-201020
  • Short report

CD24: a potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma

  1. Francesco A Mauri2
  1. 1Department of Experimental Medicine, Imperial Center for Translational and Experimental Medicine, Imperial College London, London, UK
  2. 2Department of Histopathology, Imperial College London, London, UK
  3. 3Department of Medical Oncology, Imperial College London, London, UK
  1. Correspondence to Dr Francesco A Mauri, Department of Histopathology, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0HS, UK; f.mauri{at}imperial.ac.uk
  • Received 21 June 2012
  • Revised 12 August 2012
  • Accepted 12 September 2012
  • Published Online First 19 October 2012

Abstract

Background The differential diagnosis between malignant mesothelioma (MM) and metastatic lung adenocarcinoma (MLA) often relies on immunohistochemical studies, with no individual immunomarker holding satisfactory discrimination ability.

Methods We investigated the diagnostic accuracy of CD24 immunoreactivity on 134 patients including 69 cases of MM and 65 MLA.

Results The expression of CD24 favoured MLA, with 57/65 cases showing positive cytoplasmic staining compared with 9/69 MM (p<0.001), whose immunopositivity pattern was prevalently membranous (7/9 cases).

Conclusions CD24 positivity can accurately discriminate MM from MLA. Prospective studies are warranted to clarify whether CD24 could integrate with other immunomarkers to facilitate the diagnosis of mesothelial malignancies.